Back to Search
Start Over
Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) – Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial
- Source :
- Clinical Lymphoma Myeloma and Leukemia. 19:S221-S222
- Publication Year :
- 2019
- Publisher :
- Elsevier BV, 2019.
- Subjects :
- Cancer Research
Oncology
Hematology
Subjects
Details
- ISSN :
- 21522650
- Volume :
- 19
- Database :
- OpenAIRE
- Journal :
- Clinical Lymphoma Myeloma and Leukemia
- Accession number :
- edsair.doi...........3c432a087a8f11d62bec8ae33c9d8c88